NASDAQ:AFMD Affimed (AFMD) Stock Forecast, Price & News $0.46 -0.01 (-2.11%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$0.45▼$0.4950-Day Range$0.46▼$0.6352-Week Range$0.45▼$2.55Volume403,034 shsAverage Volume958,926 shsMarket Capitalization$69.23 millionP/E RatioN/ADividend YieldN/APrice Target$5.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Affimed MarketRank™ ForecastAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside1,086.4% Upside$5.50 Price TargetShort InterestHealthy1.48% of Shares Sold ShortDividend StrengthN/ASustainability-1.95Upright™ Environmental ScoreNews Sentiment0.27Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.85) to ($0.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.34 out of 5 starsMedical Sector418th out of 964 stocksBiotechnology Industry13th out of 26 stocks 3.4 Analyst's Opinion Consensus RatingAffimed has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.50, Affimed has a forecasted upside of 1,086.4% from its current price of $0.46.Amount of Analyst CoverageAffimed has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.48% of the outstanding shares of Affimed have been sold short.Short Interest Ratio / Days to CoverAffimed has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Affimed has recently decreased by 1.34%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAffimed does not currently pay a dividend.Dividend GrowthAffimed does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAffimed has received a 62.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Cancer medication (L01)" product. See details.Environmental SustainabilityThe Environmental Impact score for Affimed is -1.95. Previous Next 2.4 News and Social Media Coverage News SentimentAffimed has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Affimed this week, compared to 1 article on an average week.Search InterestOnly 11 people have searched for AFMD on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.MarketBeat Follows4 people have added Affimed to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Affimed insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.80% of the stock of Affimed is held by insiders.Percentage Held by InstitutionsOnly 30.82% of the stock of Affimed is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Affimed are expected to grow in the coming year, from ($0.85) to ($0.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Affimed is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Affimed is -0.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAffimed has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Affimed (NASDAQ:AFMD) StockAffimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.Read More AFMD Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AFMD Stock News HeadlinesSeptember 27, 2023 | americanbankingnews.comAffimed (NASDAQ:AFMD) Coverage Initiated by Analysts at StockNews.comSeptember 26, 2023 | americanbankingnews.comAffimed (NASDAQ:AFMD) Given "Overweight" Rating at Cantor FitzgeraldSeptember 27, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.September 25, 2023 | benzinga.comWhat 6 Analyst Ratings Have To Say About AffimedSeptember 24, 2023 | americanbankingnews.comAffimed (NASDAQ:AFMD) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 23, 2023 | americanbankingnews.comAffimed (NASDAQ:AFMD) Share Price Crosses Below 200-Day Moving Average of $0.69September 21, 2023 | finance.yahoo.comAffimed to Present at the Cantor Global Healthcare Conference 2023September 12, 2023 | markets.businessinsider.comAffimed Says FDA Grants Fast Track Designation For AFM13 With AlloNK To Treat R/r Hodgkin LymphomaSeptember 27, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.September 7, 2023 | msn.comCantor Fitzgerald Reiterates Affimed N.V. (AFMD) Overweight RecommendationSeptember 7, 2023 | markets.businessinsider.comExpert Ratings for AffimedAugust 23, 2023 | finance.yahoo.comIs Affimed NV Set to Underperform? Analyzing the Factors Limiting GrowthAugust 22, 2023 | finance.yahoo.comAffimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal DevelopabilityAugust 16, 2023 | barrons.comAffimed N.V.August 11, 2023 | markets.businessinsider.comWhere Affimed Stands With AnalystsAugust 11, 2023 | markets.businessinsider.comAffimed (AFMD) Gets a Buy from H.C. WainwrightAugust 11, 2023 | msn.comTruist Securities Maintains Affimed N.V. (AFMD) Buy RecommendationAugust 11, 2023 | finanznachrichten.deAffimed N.V.: Affimed Reports Second Quarter 2023 Financial Results and Highlights Operational ProgressAugust 9, 2023 | seekingalpha.comAffimed Q2 2023 Earnings PreviewAugust 9, 2023 | finance.yahoo.comSome Analysts Just Cut Their Affimed N.V. (NASDAQ:AFMD) EstimatesAugust 3, 2023 | finance.yahoo.comAffimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023August 1, 2023 | benzinga.comAffimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech's SNK01 NK CellsJuly 31, 2023 | finance.yahoo.comAffimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech’s SNK01 NK CellsJune 22, 2023 | finanznachrichten.deAffimed N.V.: Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory BoardJune 22, 2023 | finance.yahoo.comAffimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory BoardJune 9, 2023 | finance.yahoo.comAffimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML)June 6, 2023 | finance.yahoo.comAffimed (NASDAQ:AFMD) shareholders have endured a 78% loss from investing in the stock three years agoSee More Headlines Receive AFMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter. Email Address AFMD Company Calendar Last Earnings8/10/2023Today9/27/2023Next Earnings (Estimated)11/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AFMD CUSIPN/A CIK1608390 Webwww.affimed.com Phone496221674360Fax49-6221-653-0777Employees219Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.50 High Stock Price Forecast$7.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+1,086.4%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-90,610,000.00 Net Margins-357.49% Pretax Margin-359.20% Return on Equity-79.96% Return on Assets-60.31% Debt Debt-to-Equity Ratio0.09 Current Ratio5.05 Quick Ratio5.03 Sales & Book Value Annual Sales$43.58 million Price / Sales1.59 Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book0.35Miscellaneous Outstanding Shares149,340,000Free Float143,664,000Market Cap$69.23 million OptionableOptionable Beta2.11 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Adi Hoess M.D. (Age 62)Ph.D., CEO, MD & Member of Management Board Comp: $815.34kMr. Angus W. Smith (Age 41)CFO & Member of Management Board Comp: $671.27kDr. Wolfgang Fischer (Age 59)MD, COO & Member of Management Board Comp: $636.05kMs. Denise Mueller (Age 53)Chief Bus. Officer & Member of Management Board Comp: $618.98kDr. Andreas Harstrick M.D. (Age 62)Chief Medical Officer & Member of Management Board Comp: $527.2kDr. Arndt Justus Georg Schottelius M.D. (Age 57)Ph.D., Chief Scientific Officer & Member of Management Board Comp: $639.25kProf. Melvyn LittleFounder & ConsultantMr. Michael Wolf (Age 56)Head of Fin. & Admin. Mr. Alexander FudukidisHead of Investor Relations & Director of Investor RelationsMary Beth SandinVP of Marketing & CommunicationsMore ExecutivesKey CompetitorsSurface OncologyNASDAQ:SURFImmix BiopharmaNASDAQ:IMMXCara TherapeuticsNASDAQ:CARAKodiak SciencesNASDAQ:KODeFFECTOR TherapeuticsNASDAQ:EFTRView All CompetitorsInstitutional OwnershipBarclays PLCSold 83,043 shares on 9/21/2023Ownership: 0.050%Goldman Sachs Group Inc.Bought 48,178 shares on 8/15/2023Ownership: 0.206%Wells Fargo & Company MNSold 32,165 shares on 8/15/2023Ownership: 0.118%Royal Bank of CanadaSold 21,045 shares on 8/15/2023Ownership: 0.031%Citadel Advisors LLCBought 3,300 shares on 8/15/2023Ownership: 0.000%View All Institutional Transactions AFMD Stock - Frequently Asked Questions Should I buy or sell Affimed stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AFMD shares. View AFMD analyst ratings or view top-rated stocks. What is Affimed's stock price forecast for 2023? 8 Wall Street research analysts have issued 12 month price objectives for Affimed's shares. Their AFMD share price forecasts range from $1.00 to $7.00. On average, they predict the company's share price to reach $5.50 in the next year. This suggests a possible upside of 1,086.4% from the stock's current price. View analysts price targets for AFMD or view top-rated stocks among Wall Street analysts. How have AFMD shares performed in 2023? Affimed's stock was trading at $1.24 at the start of the year. Since then, AFMD shares have decreased by 62.6% and is now trading at $0.4636. View the best growth stocks for 2023 here. When is Affimed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023. View our AFMD earnings forecast. How were Affimed's earnings last quarter? Affimed (NASDAQ:AFMD) released its quarterly earnings data on Thursday, August, 10th. The biopharmaceutical company reported ($0.22) EPS for the quarter, meeting analysts' consensus estimates of ($0.22). The biopharmaceutical company earned $1.51 million during the quarter, compared to analyst estimates of $4.83 million. Affimed had a negative trailing twelve-month return on equity of 79.96% and a negative net margin of 357.49%. What other stocks do shareholders of Affimed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Affimed investors own include Novavax (NVAX), JetBlue Airways (JBLU), SentinelOne (S), American International Group (AIG), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Amarin (AMRN), Rigel Pharmaceuticals (RIGL), Viking Therapeutics (VKTX) and Lipocine (LPCN). What is Affimed's stock symbol? Affimed trades on the NASDAQ under the ticker symbol "AFMD." Who are Affimed's major shareholders? Affimed's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.82%), Renaissance Technologies LLC (0.39%), State Street Corp (0.38%), BNP Paribas Arbitrage SNC (0.35%), Intellectus Partners LLC (0.28%) and Goldman Sachs Group Inc. (0.21%). How do I buy shares of Affimed? Shares of AFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Affimed's stock price today? One share of AFMD stock can currently be purchased for approximately $0.46. How much money does Affimed make? Affimed (NASDAQ:AFMD) has a market capitalization of $69.23 million and generates $43.58 million in revenue each year. The biopharmaceutical company earns $-90,610,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis. How many employees does Affimed have? The company employs 219 workers across the globe. How can I contact Affimed? Affimed's mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The official website for the company is www.affimed.com. The biopharmaceutical company can be reached via phone at 496221674360, via email at ir@affimed.com, or via fax at 49-6221-653-0777. This page (NASDAQ:AFMD) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.